Polowang

Biography

 TAIPEI, TAIWAN--(Marketwired - Jun 19, 2016) - According to the statistics of International Agency for Research on Cancer (IARC), cancer is among the leading cause of morbidity and mortality worldwide, with an average of 14 million new cancer cases and 8.2 million cancer-related deaths per year. In addition, the number of new cases is expected to rise by about 70% over the next 2 decades. Today, cancer is still an unpredictable life event. Most people are unable to accurately calculate the risk of cancer, even though they have periodic cancer-related health check-ups or a CT scan every half year. Under the situation, many people are emotionally and financially unprepared for cancer when they are first informed about from the doctor. Therefore, PoloWang Biotech Inc., a direct-to-consumer (DTC) genetic testing company, successfully developed the latest genetic screening techniques to detect clonal low level oncogenic mutations from circulating tumor DNA, (ctDNA) and intact circulating tumor cells (CTC). The patents of technological inventions have been applied for more than 10 countries, and been officially granted in Taiwan, Mainland China, and Australia. The characteristics of this technique is capable to accurately detect DNA mutations in only 10ml of whole blood and then calculate the individual risk of cancer for further cancer prevention. In addition, PoloWang Biotech Inc. earns ISO 13485:2003 Certification and produces various high-quality mutation detection kits. In order to help users to get the genetic testing more easier based on the concept of Direct-to-consumer (DTC), PoloWang Biotech Inc. developed a O2O cross-platform software (GenonFire) with three different interfaces to integrate end users, community clinics, and clinical laboratory all together into this cloud-based application.

Research Interest

genetics, Cancer genomics